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The widespread introduction of highly active antiretroviral
therapy (HAART) in 1996 has revolutionised the prognosis of
HIV disease [1–3]. The incidence of death from AIDS has
fallen markedly and many opportunistic infections have
become relatively rare. Consequently, the pattern of referrals
to the intensive care unit (ICU) has altered. It is important to
appreciate, however, that in spite of advances in treatment,
30% of new HIV diagnoses are made when patients are
already severely immunocompromised; the patient may be
presenting with AIDS for the first time [4]. A dilemma arises
when a patient on HAART is admitted to the ICU. Unless the
admission is directly related to HAART, there is little
consensus on what to do in terms of continuing treatment.
HAART enables the immune system to function relatively
normally and has demonstrable benefit in at least two areas
impinging on ICU. Viral load is suppressed in patients on
haemodialysis, and morbidity and mortality is considerably
reduced [5]. Similarly the incidence of both community- and
hospital-acquired pneumonia is reduced in patients on
HAART [6]. There are little data showing how HAART
patients respond to treatment of nonHIV related conditions.
However, the impact on immunity, the reduction in morbidity
from dialysis, and the reduction in pneumonia are all
circumstantial evidence that patients on HAART are more
resilient and therefore potentially more responsive, at least to
infective problems.
The second group of patients with HIV may have developed
resistance to some or all of their antiretroviral therapy. These
patients continue to have poorly controlled viral replication,
and are at risk of opportunistic infection as their immune
suppression continues.
The third group of patients with HIV may have an acute
illness that is immunosuppressive in nature. If HAART is
discontinued on admission to ICU, the risk of further
opportunistic infections for these patients will increase
dramatically [7].
The fourth and final group may be presenting with
complications directly related to their antiretroviral therapy,
such as lactic acidosis and pancreatitis [8,9]. Nucleoside
analogues such as zidovudine or stavudine have been
associated with the development of mitochondrial
dysfunction [10,11]. The drugs can inhibit mitochondrial DNA
polymerase gamma, causing abnormalities in the respiratory
chain and life-threatening lactic acidosis. Pancreatitis may be
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Abstract
The risks and benefits of stopping antiretroviral therapy in patients admitted to the ICU are largely
unmeasured. In many cases therapy has to be stopped, as parenteral preparations are unavailable for all
but one of the antiretroviral agents. Stopping treatment suddenly may be associated with increased risk of
resistance because of the long half-life of some of the drugs, and also the risk of increased
immunosuppression due to the viral load rebounding. Drugs given through the enteral route may be poorly
absorbed, which again may lead to drug resistance. By inhibiting cytochrome P450 3A4 the drugs
interfere with the metabolism of many other compounds routinely used in the ICU. Furthermore, the drugs
themselves are occasionally associated with severe toxicity such as pancreatitis and lactic acidosis, which
can have devastating consequences. Much active research in all of these areas is now needed.
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part of this syndrome but is also related to the use of specific
antiretroviral drugs, such as didanosine. Some protease
inhibitors may cause large increases in cholesterol,
triglycerides, and glucose, which can lead to severe acute
metabolic complications.
Non-nucleosides, such as Nevaripine, have been associated
with hepatic failure. Other, more rare, syndromes, such as
uncontrolled fits in neonates and severe hypotension, have
been reported with other HIV drugs. Liver toxicity is a major
concern with HAART, in its own right and in combination with
certain other agents used in ICU, especially in patients with
chronic viral hepatitis.
Resistance, absorption, and interactions
The critically ill patient on antiretroviral drugs is a challenge.
Much of what is done is based on physician experience rather
than data from controlled studies. Clearly, if the presenting
condition is related to the HIV therapy, the drugs must be
stopped. It is often difficult to substitute with alternative
regimes because of overlapping toxicities, previous drug
resistance, or difficulties in administrating the drug. When
patients are nil by mouth abruptly stopping antiretroviral
therapy may cause a sudden fall in CD4+ cell count and a rise
in viral load. Some patients may even develop an acute
seroconversation illness. Interestingly, however, stopping and
starting HAART is a strategy used for trying to enhance
immune responses to HIV in asymptomatic patients [12].
Discontinuing some drugs, such as the non-nucleosides, may
even lead to drug resistance. Once they are stopped, some
drugs exist in the plasma and cells for several days at sub-
therapeutic levels because their half-lives are 3–5 days.
Once the drugs are discontinued, the virus replicates and re-
emerges in the plasma. This may enable the virus to develop
resistance to the drug.
Resistance may also occur because of poor drug absorption.
If plasma and cellular levels of some of the compounds are
not adequate then resistance can occur after relatively few
doses of the non-nucleosides or lamivudine.
Unfortunately, most antiretroviral drugs can only be given in
patients with a normally functioning gut and who can be fed
orally or through a nasogastric tube. Zidovudine is the only
drug that can be given intravenously. There are few data on
the absorption and pharmacokinetics of any of the
antiretrovirals when given through a gastric or jejunal feeding
tube. Drug levels can be measured for protease inhibitors
[13] and non-nucleosides but plasma levels are not reliable
for nucleosides, which are activated by intracellular
phosphorylation.
Drug interactions are important, especially when enzymes
inducers, such as phenytoin and rifampicin, are used. There
are still relatively few data on the interactions between many
of the drugs used in the ICU and those used in HIV therapy.
The protease inhibitors and the non-nucleosides can act as
cytochrome P450 3A4 inhibitors, and affect the metabolism of
many of the drugs used in ICU, such as midazolam or opiates.
In practical terms it makes sense to continue HIV treatment
where possible. The consequences of stopping treatment
may be serious, and research is needed on drug absorption
and stopping-and-starting therapy in the ICU, as well as drug
interactions. The effect of HAART on ICU outcomes, either
directly or indirectly through its effect on viral load and CD4+
cells, needs to be explored.
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